5057-51-2

Basic information

• Product Name: 4-(3-CHLORO-PHENOXY)-BUTYRIC ACID
• Synonyms: 4-(3-CHLORO-PHENOXY)-BUTYRIC ACID;Butanoic acid, 4-(3-chlorophenoxy)-
• CAS NO: 5057-51-2
• Molecular Formula: C₁₀H₁₁ClO₃
• Molecular Weight: 214.65
• Mol File: 5057-51-2.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 383.1°C at 760 mmHg
• Flash Point: 185.5°C
• Appearance: /
• Density: 1.266g/cm³
• Vapor Pressure: 1.49E-06mmHg at 25°C
• Refractive Index: 1.541
• CAS DataBase Reference: 4-(3-CHLORO-PHENOXY)-BUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-CHLORO-PHENOXY)-BUTYRIC ACID(5057-51-2)
• EPA Substance Registry System: 4-(3-CHLORO-PHENOXY)-BUTYRIC ACID(5057-51-2)

Safety Data

• Hazardous Substances Data: 5057-51-2(Hazardous Substances Data)

Usage

General Description

4-(3-chloro-phenoxy)-butyric acid is a chemical compound with the molecular formula C10H11ClO3. It is a chlorinated derivative of phenoxybutyric acid and is commonly used as a plant growth regulator to stimulate the growth of roots in various crops. 4-(3-CHLORO-PHENOXY)-BUTYRIC ACID is often applied to seeds, cuttings, or transplants to promote root development and improve overall plant vigor. Additionally, it has been studied for its potential use in controlling unwanted sprouting in stored potatoes and as a herbicide to control the growth of certain weeds. However, it is important to note that this chemical should be handled with care due to its potential toxicity and environmental impact.

InChI:InChI=1/C10H11ClO3/c11-8-3-1-4-9(7-8)14-6-2-5-10(12)13/h1,3-4,7H,2,5-6H2,(H,12,13)

Upstream product

• 96-48-0 4-butanolide 
• 108-43-0 3-monochlorophenol 
• 1007476-32-5 sodium ethyl acetylacetate enolate 
• 37483-53-7 ethyl 4-(3-chlorophenoxy)butanoate 
• 5057-52-3 4-(2-chlorophenoxy)butanoic acid 
• 111105-19-2 ethyl 4-(2-chlorophenoxy)butanoate 
• 95-57-8 2-monochlorophenol 
• 37142-46-4 1-(3-bromopropoxy)-3-chlorobenzene 
• 64-17-5 ethanol 
• 108-37-2 1-bromo-3-chlorobenzene 

Downstream Products

• 37483-53-7 ethyl 4-(3-chlorophenoxy)butanoate 
• 1240998-36-0 8-chloro-1-(2,4-dichlorophenyl)-N-(6,6-dimethyl-bicyclo[3.1.1]hept-2-yl-methyl)-4,5-dihydrobenzo-1H-6-oxa-cyclohepta[1,2-c]pyrazole-3-carboxamide 

Relevant articles and documents

Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1

Due to the increasing resistance of Pseudomonas aeruginosa to most clinically relevant antimicrobials, it is challenging to treat bacterial infection with traditional antibiotics. Quorum sensing can regulate the production of biofilms and virulence factors which are closely related to bacterial resistance. Previously we synthesized a series of oxazolidinone compounds targeting the quorum-sensing transcriptional regulatory protein CviR and ZS-12 showed good activity against Chromobacterium violaceum CV026 quorum-sensing. In this study, eighteen 3-amino-2-oxazolidinone compounds were designed and synthesized using ZS-12 as the lead compound. We initially evaluated the inhibitory activities of novel oxazolidinone compounds against QS using C. violaceum CV026 as a reporter strain. Thirteen compounds showed good activities (IC50 range 3.69–63.58 μM) and YXL-13 inhibition was the most significant (IC50 = 3.686 ± 0.5790 μM) against biofilm formation and virulence factors determination of P. aeruginosa PAO1. In vitro, YXL-13 significantly inhibited the formation of PAO1 biofilm (range 42.98%–17.67%), the production of virulence factors (pyocyanin, elastase, rhamnolipid, and protease), and bacterial motility. Moreover, the combination of YXL-13 with an antibiotic (meropenem trihydrate) could significantly improve the antibiotic susceptibility of biofilm P. aeruginosa PAO1 cells. In vivo, YXL-13 significantly prolonged the lifespan of wildtype Caenorhabditis elegans N2 infected by P. aeruginosa PAO1. In conclusion, YXL-13 is a candidate agent for antibiotic-resistant P. aeruginosa PAO1and provides a method for finding new antibacterial drugs.

Development of oxygen-bridged pyrazole-based structures as cannabinoid receptor 1 ligands

In this work, the synthesis of the cannabinoid receptor 1 neutral antagonists 8-chloro-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-4,5-dihydrobenzo-1H-6-oxa-cyclohepta[1,2-c] pyrazole-3-carboxamide 1a and its deaza N-cyclohexyl analogue 1b has led to a deepening of the structure-activity studies of this class of compounds. A series of novel 4,5-dihydrobenzo-oxa-cycloheptapyrazoles analogues of 1a,b, derivatives 1c-j, was synthesized, and their affinity towards cannabinoid receptors was determined. Representative terms were evaluated using in vitro tests and isolated organ assays. Among the derivatives, 1d and 1e resulted in the most potent CB1 receptor ligands (KiCB1 = 35 nM and 21.70 nM, respectively). Interestingly, both in vitro tests and isolated organ assays evidenced CB1 antagonist activity for the majority of the new compounds, excluding compound 1e, which showed a CB1 partial agonist behaviour. CB1 antagonist activity of 1b was further confirmed by a mouse gastrointestinal transit assay. Significant activity of the new CB1 antagonists towards food intake was showed by preliminary acute assays, evidencing the potentiality of these new derivatives in the treatment of obesity.

Pharmaceutical compounds wiht angiogenesis inbhibitory activity

Compounds of formula (I): wherein: A, R, T, Q, L, Z, G, X and A' are as defined in the description. B and D, equal to or different from each other, are selected between heteroaryl and aryl, wherein at least one of the hydrogen atoms of said heteroaryl and aryl are substituted with groups selected from SO3-, SO3H, COO-, COOH, and one or more of the other hydrogen atoms of said heteroaryl and aryl are optionally substituted as reported in the description.